# SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

> **NCT01470469** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 83 (actual)

## Conditions studied

- Generalized Anxiety Disorder (GAD)
- Anxiety, Separation
- Phobia, Social

## Interventions

- **DRUG:** SPD503 (extended-release Guanfacine hydrochloride)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01470469
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-04
- **Primary completion:** 2013-07-15
- **Final completion:** 2013-07-15
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470469, "SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01470469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*